Allspring Global Investments’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Allspring Global Investments’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-721	Closed	-$73.5K	–	2930
2023 Q2	$73.5K	Sell	721 -532	-42%	-$50.3K	﹤0.01%	2164
2023 Q1	$114K	Buy	+1,253	New	+$73.5K	﹤0.01%	2004
2022 Q2	–	Sell	-3,313	Closed	-$108K	–	3018
2022 Q1	$108K	Sell	3,313 -380	-10%	-$11.3K	﹤0.01%	2735
2021 Q4	$97K	Buy	+3,693	New	+$286K	﹤0.01%	2771

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Allspring Global Investments's RETA Position: Q3 2023 in Review

Allspring Global Investments sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 721 shares — an estimated $73.5K sold.

Allspring Global Investments first reported a position in RETA in Q4 2021 and held it in 4 quarters. The position peaked at $114K in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Allspring Global Investments reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Allspring Global Investments sold 721 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $73.5K.
Allspring Global Investments first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2021 and held it in 4 quarters.
Allspring Global Investments's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $114K in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Allspring Global Investments's 13F filing for Q3 2023, filed 27 Oct 2023.